HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) All Versions of this Article: dc07-1736v1 31/2/199    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Monami, M. Articles by Mannucci, E. Search for Related Content PubMed PubMed Citation Articles by Monami, M. Articles by Mannucci, E. Social Bookmarking                What's this?

BONE FRACTURES AND HYPOGLYCAEMIC TREATMENT IN TYPE 2 DIABETIC PATIENTS: A CASE-CONTROL STUDY.

¹Department of Critical Care Medicine and Surgery, Unit of Geriatrics, University of Florence and AOU Careggi, Florence, Italy
²Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence and AOU Careggi, Italy
³Epidemiology Unit, Local Health Unit 10, Florence, Italy

edoardo.mannucci{at}fastwebnet.it

ABSTRACT

Background: Hypoglycaemic treatments could modulate the risk for fractures in many ways. Most studies have not explored the effect on the incidence of bone fractures of individual oral hypoglycaemic agents, considering all oral treatments only as a whole. Aim of this case-control study, nested within a retrospective cohort, is the assessment of the risk for bone fractures associated with exposure to insulin or different oral hypoglycaemic agents.

Materials and methods: A case-control study nested within a cohort of 1,945 diabetic outpatients with a follow-up of 4.1±2.3 years was performed, comparing 83 cases of bone fractures and 249 controls matched for age, sex, duration of diabetes, BMI, HbA1_c, comorbidity, smoking and alcohol abuse. Exposure to hypoglycemic drugs during the 10 years preceding the event (or matching index date) was assessed.

Results: In a model including treatment with insulin-secretagogues, metformin and insulin for at least 36 months during the previous ten years, no significant association was observed between bone fractures and medications. In an alternative model considering treatments at the time of fracture, insulin treatment was significantly associated with bone fractures in men (OR,95%CI:3.20[1.32;7.74]), but not in women (OR:1.41[0.73;2.73]).

Conclusion: Insulin-sensitizing treatment with metformin is not associated with a higher incidence of bone fractures, suggesting that the negative effect of thiazolidinediones is due to a specific action on bone metabolism, rather than to reduction of insulinemia. Conversely, current treatment with insulin increases the risk of fractures; at the same time, exposure to this agent in the longer term does not appear to affect bone frailty.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?